Effect of selective COX-2 inhibition on neuroinflammation in Parkinson's disease - COXPKPD
- Conditions
- Parkinson's disease
- Registration Number
- EUCTR2007-001206-24-NL
- Lead Sponsor
- MCG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 20
-Age over 40
-Informed consent.
-Regarded by the treating physician to have competence of judgement.
-Compliance with the criteria for possible or probable PD as proposed by Gelb, Oliver and Gilman [1999]
-early stage PD; Hoehn and Yahr stages 1-2.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
- Prior cardiovascular brain disease, other brain disease (including former traumatic contusion)
- Evidence of any significant general medical disease in medical history or at clinical exam; e.g. significant kidney or liver disease, evidence of autoimmune disease.
- Evidence of psychiatric disease in medical history; e.g. depressive disorder, schizophrenia.
- Use of anti-inflammatory medication: NSAID’s and steroids.
- Use of benzodiazepines. Benzodiazepines have affinity for the PBR receptor that binds the PET tracer PK11195 and can interfere with the study.
- Contra-indications for celecoxib use: active gastric ulcers or gastric bleeding. Asthma attack, urticaria, angio-edema after use of prostaglandine synthetase inhibitors. Inflammatory bowel disease. Moderate or severe liver or kidney disease. Severe heart failure. Allergy to sulphonamide.
- Abnormalities at clinical neurological examination (other than PD)
- Pregnancy in women of childbearing potential.
- Exposure to a significant amount of radiation in the past year.
- Radiological workers.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method